Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 4/20 | 0.44 |
| ▸ | MTNR1B | P49286 | 4/20 | 0.44 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.42 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.40 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.40 |
| ▸ | CASR | P41180 | 2/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9392741 | 0.83 | MTNR1A (0.58) | MTNR1AMTNR1BAOC3L3MBTL1ROCK2 | |
| SCHEMBL6301269 | 0.80 | MTNR1A (0.63) | MTNR1AMTNR1BAOC3L3MBTL1ROCK2 | |
| SCHEMBL9658024 | 0.78 | MTNR1A (0.49) | MTNR1AMTNR1BAOC3L3MBTL1ROCK2 | |
| SCHEMBL8661020 | 0.73 | AOC3 (0.54) | MTNR1AMTNR1BAOC3L3MBTL1CASR | |
| SCHEMBL4161413 | 0.73 | TSHR (0.44) | MTNR1AMTNR1BENPP2 | |
| SCHEMBL11174933 | 0.72 | AOC3 (0.50) | MTNR1AMTNR1BAOC3L3MBTL1ROCK2 | |
| SCHEMBL6490320 | 0.72 | AOC3 (0.62) | MTNR1AMTNR1BAOC3L3MBTL1ROCK2 | |
| SCHEMBL24527630 | 0.71 | AOC3 (0.53) | MTNR1AMTNR1BAOC3L3MBTL1ROCK2 | |
| SCHEMBL382558 | 0.71 | AOC3 (0.53) | MTNR1AMTNR1BAOC3L3MBTL1ROCK2 | |
| SCHEMBL11468299 | 0.71 | AOC3 (0.59) | MTNR1AMTNR1BAOC3L3MBTL1ROCK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090029947-A1 | Sphingosine-1-phosphate receptor agonist and antagonist compounds | ABBVIE INC. | 2009-01-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090029947-A1 | Sphingosine-1-phosphate receptor agonist and antagonist compounds | S1PR1, S1PR3, S1PR5 | MTNR1A 255/4885MTNR1B 245/4885ENPP2 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.